On Oct. 6, 2021, Lumen Bioscience announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support was provided by the US Army Medical Research and Development Command.

This announcement built on a previous Army grant to Lumen that funded preclinical development of LMN-301, an investigational product directed at treating and preventing the gastrointestinal (GI) manifestations of Covid-19.